UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 76.

Combes, J D; Clifford, G M; Egger, M; Cavassini, M; Hirsch, H; Hauser, C; Calmy, A; Schmid, P; Bernasconi, E; Gunthard, H F; Franceschi, S; Waterboer, T; Scherrer, A U (2016). Human papillomavirus antibody response following highly active antiretroviral therapy initiation among men who have sex with men. AIDS, 31(4):561-569.

Aebi-Popp, K; Kouyos, R; Bertisch, B; Staehelin, C; Rudin, C; Hoesli, I; Stoeckle, M; Bernasconi, E; Cavassini, M; Grawe, C; Lecompte, T D; Rickenbach, M; Thorne, C; Martinez de Tejada, B; Fehr, J (2016). Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period. HIV Medicine, 17(4):280-288.

Schaerer, V; Haubitz, S; Kovari, H; Ledergerber, B; Ambrosioni, J; Cavassini, M; Stoeckle, M; Schmid, P; Decosterd, L; Aouri, M; Böni, J; Günthard, H F; Furrer, H; Metzner, K J; Fehr, J; Rauch, A (2015). Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Medicine, 16(10):599-607.

Schäfer, J; Young, J; Bernasconi, E; Ledergerber, B; Nicca, D; Calmy, A; Cavassini, M; Furrer, H; Battegay, M; Bucher, H C; Swiss HIV Cohort Study (2015). Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 16(1):3-14.

Itin, P; Bosshard, P; Toutous-Trellu, L; Schmidt, A J; Vernazza, P; Tarr, P; Stoeckle, M; Wymann, M P; Ciardo, D; Walser, S; Claass, J; Scheidegger, C; Lowe, N; Oertle-Meyer, D; Cavassini, M; Schmid, P; Bernasconi, E; Haerry, D; Boffi-El Amari, E; Herold, M; Klimkait, T; Kahlert, C; Furrer, H J; Lautenschlager, S; Calmy, A; Fehr, J (2015). Syphilis: diagnostic and treatment. Swiss Medical Forum, 19:459-465.

Metzner, K J; Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Hirsch, H; Vernazza, P L; Cavassini, M; Calmy, A; Bernasconi, E; Weber, R; Gunthard, H F (2014). Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS, 28(15):2231-2239.

Arab-Alameddine, M; Lubomirov, R; Fayet-Mello, A; Aouri, M; Rotger, M; Buclin, T; Widmer, N; Gatri, M; Ledergerber, B; Rentsch, K; Cavassini, M; Panchaud, A; Guidi, M; Telenti, A; Décosterd, L A; Csajka, C (2014). Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 69(9):2489-2498.

Kouyos, R D; Rauch, A; Braun, D L; Yang, W-L; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Shah, C; Kovari, H; Calmy, A; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Gunthard, H F (2014). Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 210(10):1555-1561.

Hasse, B; Iff, M; Ledergerber, B; Calmy, A; Schmid, P; Hauser, C; Cavassini, M; Bernasconi, E; Marzolini, C; Tarr, P E; Aubert, V; Barth, J; Battegay, M; Bernasconi, E; Boni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Egger, M; Elzi, L; Fehr, J; Fellay, J; Furrer, H; Fux, C A; Gorgievski, M; Gunthard, H; Haerry, D; Hasse, B; Hirsch, H H; Hosli, I; Kahlert, C; Kaiser, L; Keiser, O; Klimkait, T; Kouyos, R; Kovari, H; Ledergerber, B; Martinetti, G; Martinez de Tejada, B; Metzner, K; Muller, N; Nadal, D; Pantaleo, G; Rauch, A; Regenass, S; Rickenbach, M; Rudin, C; Schoni-Affolter, F; Schmid, P; Schultze, D; Schupbach, J; Speck, R; Staehelin, C; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2014). Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study. Open Forum Infectious Diseases, 1(2):ofu040.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Staehelin, C; Keiser, O; Calmy, A; Weber, R; Elzi, L; Cavassini, M; Schmid, P; Bernasconi, E; Furrer, H (2012). Longer term clinical and virological outcome of Sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 59(1):79-85.

Clifford, G M; Lise, M; Franceschi, S; Egger, M; Bouchardy, C; Korol, D; Levi, F; Ess, S; Jundt, G; Wandeler, G; Fehr, J; Schmid, P; Battegay, M; Bernasconi, E; Cavassini, M; Calmy, A; Keiser, O; Schöni-Affolter, F (2012). Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. British Journal of Cancer, 106(3):447-452.

Keiser, O; Spycher, B; Rauch, A; Calmy, A; Cavassini, M; Glass, T R; Nicca, D; Ledergerber, B; Egger, M (2012). Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: Latent class analysis. AIDS and Behavior, 16(2):245-255.

Thierfelder, C; Weber, R; Elzi, L; Furrer, H; Cavassini, M; Calmy, A; Bernasconi, E; Gutmann, C; Ledergerber, B (2012). Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV Medicine, 13(2):118-126.

Marzolini, C; Back, D; Weber, R; Furrer, H; Cavassini, M; Calmy, A; Vernazza, P; Bernasconi, E; Khoo, S; Battegay, M; Elzi, L (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9):2107-2111.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Rieder, P; Joos, B; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Rauch, A; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases, 52(4):532-539.

Lubomirov, R; Colombo, S; di Iulio, J; Ledergerber, B; Martinez, R; Cavassini, M; Hirschel, B; Bernasconi, E; Elzi, L; Vernazza, P; Furrer, H; Günthard, H F; Telenti, A (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. Journal of Infectious Diseases, 203(2):246-257.

El Amari, E B; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV Medicine, 12(7):394-402.

von Wyl, V; Gianella, S; Fischer, M; Niederoest, B; Kuster, H; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE, 6(11):e27463.

Gianella, S; von Wyl, V; Fischer, M; Niederoest, B; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antiviral Therapy, 16(4):535-545.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

Kenfak-Foguena, A; Schöni-Affolter, F; Bürgisser, P; Witteck, A; Darling, K E A; Kovari, H; Kaiser, L; Evison, J M; Elzi, L; Gurter-De La Fuente, V; Jost, J; Moradpour, D; Abravanel, F; Izpopet, J; Cavassini, M (2011). Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerging Infectious Diseases, 17(6):1074-8.

Boillat-Blanco, Noémie; Probst, A; Da Costa, V W; Giulieri, S; Bernasconi, E; Calmy, A; Elzi, L; Rauch, A; Weber, R; Bertisch, B; Cavassini, M; Bochud, P Y (2011). Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. Journal of Acquired Immune Deficiency Syndromes, 58(5):472-474.

Elzi, L; Steffen, I; Furrer, H; Fehr, J; Cavassini, M; Hirschel, B; Hoffmann, M; Bernasconi, E; Bassetti, S; Battegay, M (2011). Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infectious Diseases, 11:319.

Scherrer, A U; Ledergerber, B; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Rauch, A; Hirschel, B; Cavassini, M; Elzi, L; Vernazza, P L; Bernasconi, E; Held, L; Günthard, H F (2011). Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical Infectious Diseases, 53(11):1143-1152.

Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E (2011). Lipid and lipoprotein profile in HIV-infected patients treated with Lopinavir/Ritonavir as a component of the first combination antiretroviral therapy. AIDS Research and Human Retroviruses, 27(5):525-533.

Hasse, B; Ledergerber, B; Furrer, H; Battegay, M; Hirschel, B; Cavassini, M; Bertisch, B; Bernasconi, E; Weber, R (2011). Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 53(11):1130-1139.

Ortiz, M; Poloni, E S; Furrer, H; Kovari, H; Martinez, R; Arnedo, M; Elzi, L; Bernasconi, E; Vernazza, P; Hirschel, B; Cavassini, M; Ledergerber, B; Günthard, H F; Telenti, A; Tarr, P E (2011). No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Journal of Infectious Diseases, 203(5):620-624.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

von Wyl, V; Kouyos, R D; Yerly, S; Böni, J; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Staehelin, C; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. Journal of Infectious Diseases, 204(7):1095-1103.

Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Medicine, 12(5):279-288.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Glass, T R; Battegay, M; Cavassini, M; De Geest, S; Furrer, H; Vernazza, P L; Hirschel, B; Bernasconi, E; Rickenbach, M; Günthard, H F; Bucher, H C (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2):197-203.

Colombo, C; Ledergerber, B; Zysset, F; Francioli, P; Cavassini, M; Ruef, C (2010). HIV-, HBV und HCV-Exposition im medizinischen Bereich in der Schweiz von 2001 bis Ende Juni 2008. BAG Bulletin, (3):36-42.

Lubomirov, R; di Iulio, J; Fayet, A; Colombo, S; Martinez, R; Marzolini, C; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Ledergerber, B; Rentsch, K; Descombes, P; Buclin, Thierry; Decosterd, L A; Csajka, C; Telenti, A (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 20(4):217-230.

Franceschi, S; Lise, M; Clifford, G M; Rickenbach, M; Levi, F; Maspoli, M; Bouchardy, C; Dehler, S; Jundt, G; Ess, S; Bordoni, A; Konzelmann, I; Frick, H; Dal Maso, L; Elzi, L; Furrer, H; Calmy, A; Cavassini, M; Ledergerber, B; Keiser, O; Swiss HIV Cohort Study (2010). Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. British Journal of Cancer, 103(3):416-422.

Hasse, B; Ledergerber, B; Hirschel, B; Vernazza, P; Glass, T R; Jeannin, A; Evison, J M; Elzi, L; Cavassini, M; Bernasconi, E; Nicca, D; Weber, R (2010). Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 51(11):1314-1322.

Rotger, M; Gsponer, T; Martinez, R; Taffé, P; Elzi, L; Vernazza, P; Cavassini, M; Bernasconi, E; Hirschel, B; Furrer, H; Weber, R; Ledergerber, B; Egger, M; Telenti, A; Tarr, P E; Swiss HIV Cohort Study (2010). Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. Clinical Infectious Diseases, 51(9):1090-1098.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Thurnheer, M C; Weber, R; Toutous-Trellu, L; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Christen, A B; Zwahlen, M; Furrer, H (2010). Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV cohort study. AIDS, 24(12):1907-1916.

Osih, R B; Taffé, P; Rickenbach, M; Gayet-Ageron, A; Elzi, L; Fux, C; Opravil, M; Bernasconi, E; Schmid, P; Günthard, H F; Cavassini, M (2010). Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Research and Human Retroviruses, 26(11):1239-1246.

Marzolini, C; Elzi, L; Gibbons, S; Weber, R; Fux, C; Furrer, H; Chave, J P; Cavassini, M; Bernasconi, E; Calmy, A; Vernazza, P; Khoo, S; Ledergerber, B; Back, D; Battegay, M (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3):413-423.

Gutmann, C; Cusini, A; Günthard, H F; Fux, C; Hirschel, B; Decosterd, L A; Cavassini, M; Yerly, S; Vernazza, P L (2010). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS, 24(15):2347-2354.

Bucher, H C; Rickenbach, M; Young, J; Glass, T R; Vallet, Y; Bernasconi, E; Cavassini, M; Fux, C; Schiffer, V; Vernazza, P; Weber, R; Battegay, M (2010). Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antiviral Therapy, 15(1):31-40.

Elzi, L; Marzolini, C; Furrer, H; Ledergerber, B; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Weber, R; Battegay, M (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1):57-65.

Clerc, O; Cavassini, M; Böni, J; Schüpbach, J; Bürgisser, P (2009). Prolonged seroconversion in an elite controller of HIV-1 infection. Journal of Clinical Virology, 46(4):371-373.

Veit, O; Niedrig, M; Chapuis-Taillard, C; Cavassini, M; Mossdorf, E; Schmid, P; Bae, H G; Litzba, N; Staub, T; Hatz, C; Furrer, H (2009). Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clinical Infectious Diseases, 48(5):659-66.

Flammer, A J; Vo, N T T; Ledergerber, B; Hermann, F; Gämperli, A; Huttner, A; Evison, J; Baumgartner, I; Cavassini, M; Hayoz, D; Quitzau, K; Hersberger, M; Sudano, I; Ruschitzka, F; Lüscher, T F; Noll, G; Weber, R (2009). Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomized controlled trial. Heart, 95(5):385-390.

Fayet, A; Béguin, A; Zanolari, B; Cruchon, S; Guignard, N; Telenti, A; Cavassini, M; Günthard, H F; Buclin, T; Biollaz, J; Rochat, B; Decosterd, L A (2009). A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. Journal of Chromatography B, 877(11-12):1057-1069.

Rotger, M; Bayard, C; Taffé, P; Martinez, R; Cavassini, M; Bernasconi, E; Battegay, M; Hirschel, B; Furrer, H; Witteck, A; Weber, R; Ledergerber, B; Telenti, A; Tarr, P E (2009). Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circulation: Cardiovascular Genetics, 2(6):621-628.

Elzi, L; Kaufmann, G; Weber, R; Fux, C A; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Battegay, M (2009). Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clinical Trials, 10(4):207-214.

Dang, T; Jaton-Ogay, K; Flepp, M; Kovari, H; Evison, J M; Fehr, J; Schmid, P; Boffi El Amari, E; Cavassini, M; Odorico, M; Tarr, P E; Greub, G (2009). High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. Clinical Infectious Diseases, 49(10):1532-1535.

Combescure, C; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV Medicine, 10(8):470-476.

Ballif, M; Ledergerber, B; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Hirschel, B; Furrer, H; Rickenbach, M; Opravil, M; Weber, R (2009). Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE, 4(12):e8275.

di Iulio, J; Fayet, A; Arab-Alameddine, M; Rotger, M; Lubomirov, R; Cavassini, M; Furrer, H; Günthard, H F; Colombo, S; Csajka, C; Eap, C B; Decosterd, L A; Telenti, A (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 19(4):300-309.

Khanna, N; Elzi, L; Mueller, N J; Garzoni, C; Cavassini, M; Fux, C A; Vernazza, P; Bernasconi, E; Battegay, M; Hirsch, H H (2009). Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clinical Infectious Diseases, 48(10):1459-1466.

Bellini, C; Keiser, O; Chave, J P; Evison, Jm; Fehr, J; Kaiser, L; Weber, R; Vernazza, P; Bernasconi, E; Telenti, A; Cavassini, M (2009). Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 10(1):12-18.

von Wyl, V; Yerli, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P; Francioli, P; Bonhoeffer, S; Ledergerber, B; Günthard, H (2009). Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical Infectious Diseases, 48(7):979-987.

Metzner, K J; Giulieri, S G; Knoepfel, S A; Rauch, P; Burgisser, P; Yerly, S; Günthard, H F; Cavassini, M (2009). Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clinical Infectious Diseases, 48(2):239-247.

Conen, A; Fehr, J; Glass, T R; Furrer, H; Weber, R; Vernazza, P; Hirschel, B; Cavassini, M; Bernasconi, E; Bucher, H C; Battegay, M (2009). Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14(3):349-357.

Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Medicine, 10(7):407-416.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

Vo, N T T; Ledergerber, B; Keiser, O; Hirschel, B; Furrer, H; Battegay, M; Cavassini, M; Bernasconi, E; Vernazza, P; Weber, R (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12):1685-1694.

El Amari, E B; Toutous-Trellu, L; Gayet-Ageron, A; Baumann, M; Cathomas, G; Steffen, I; Erb, P; Mueller, N J; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2008). Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS, 22(9):1019-1028.

HIV Cohort Study, Switzerland; von Wyl, V; Yerly, S; Klimkait, T; Böni, J; Bürgisser, P; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Rickenbach, M; Ledergerber, B; Guenthard, H F (2008). Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases, 46:1299-1309.

Wunder, D M; Fux, C A; Bersinger, N A; Mueller, N J; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H (2008). Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV Medicine, 9(6):427-432.

Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.

Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine, 9(6):397-405.

Franceschi, S; Maso, L D; Rickenbach, M; Polesel, J; Hirschel, B; Cavassini, M; Bordoni, A; Elzi, L; Ess, S; Jundt, G; Mueller, N; Clifford, G M; Swiss HIV Cohort Study (2008). Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. British Journal of Cancer, 99(5):800-804.

Rauch, A; Gaudieri, S; Evison, J; Nolan, D; Cavassini, M; Weber, R; James, I; Furrer, H; Swiss HIV Cohort Study (2008). Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antiviral Therapy, 13(3):455-460.

Rauch, A; Nolan, D; Thurnheer, C; Fux, C; Cavassini, M; Chave, J P; Opravil, M; Phillips, E; Mallal, S; Furrer, H; Swiss HIV Cohort Study (2008). Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy, 13(8):1019-1028.

Fux, C; Rauch, A; Simcock, M; Bucher, H; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss HIV Cohort Study (2008). Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 13:1077-1082.

Franceschi, S; Polesel, J; Rickenbach, M; Dal Maso, L; Probst-Hensch, N M; Fux, C; Cavassini, M; Hasse, B; Kofler, A; Ledergerber, B; Erb, P; Clifford, G M (2006). Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study. British Journal of Cancer, 95(11):1598-1602.

This list was generated on Fri Jul 21 03:41:43 2017 CEST.